Tenaya Therapeutics (TNYA) EBITDA (2020 - 2026)

Tenaya Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

• On a quarterly basis, EBITDA rose 27.14% year-over-year to -$20.1 million in Q1 2026; TTM through Mar 2026 was -$85.9 million, a 21.75% increase from a year earlier, with the FY2025 full-year figure at -$93.3 million, up 19.51% from the prior year.
• EBITDA advanced to -$20.1 million in Q1 2026 per TNYA's latest filing, from -$20.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$20.1 million in Q1 2026 and bottomed at -$35.1 million in Q2 2023.
• The 5-year median for EBITDA is -$30.8 million (2024), against an average of -$28.6 million.
• Across the five-year window, EBITDA slumped 137.73% in 2022 and advanced 27.14% in 2026, its largest moves.
• Year by year, EBITDA stood at -$34.6 million in 2022, then grew by 8.98% to -$31.4 million in 2023, then grew by 21.61% to -$24.7 million in 2024, then rose by 15.73% to -$20.8 million in 2025, then climbed by 3.42% to -$20.1 million in 2026.
• Per Business Quant, the three latest TNYA EBITDA figures stand at -$20.1 million (Q1 2026), -$20.8 million (Q4 2025), and -$20.9 million (Q3 2025).